Transpharma International

What Transpharma International does

Transpharma International is a European GDP-compliant freight forwarding and temperature-controlled logistics provider specializing in pharmaceutical and healthcare products. Founded as a dedicated entity in 2021 from the Walden Group's healthcare logistics activities (with roots traceable to 1951), the company operates pan-European road, air, and sea transport services covering all standard pharmaceutical temperature ranges: 15-25°C, 2-8°C, and -20°C. Its operations span local operating companies in the United Kingdom, France, Belgium, the Netherlands, and Germany, supported by a fleet of 200 owned vehicles and a strategic network of over 3,000 partner vehicles across Europe, augmented by a 40% stake in Poland-based Arra Group (adding 500 GDP-compliant vehicles). The company serves pharmaceutical manufacturers, medical device companies, and diagnostics companies, with primary transport, international freight forwarding, clinical trial logistics, customs and trade services, and a control tower offering as its core service portfolio.

The company's technology backbone is MyTPI, a proprietary web-based freight management system launched in Q1 2022 that provides real-time shipment tracking, temperature monitoring, document management, EDI connectivity, and direct integration with Oracle finance systems. It holds multiple compliance certifications including GDP (Good Distribution Practice), AEO-C customs certification (UK, August 2023), ISO 9001:2015, and ISO 13485 for medical device logistics. Following the December 2025 acquisition by Yusen Logistics (Europe) B.V., a subsidiary of Japan's NYK Group, Transpharma International now operates as a wholly owned subsidiary within the Yusen Logistics Healthcare network, which spans 748 locations across 46 countries and includes sister entities Movianto (warehousing/distribution), Eurotranspharma (last-mile), and Walden Digital (TMS/WMS solutions). This positions the company within a global healthcare logistics platform offering end-to-end supply chain solutions.

The business model is B2B enterprise freight forwarding and managed logistics services, with revenue generated from per-shipment and contract-based pricing for GDP-compliant transport. Customer acquisition is driven by direct enterprise field sales through Business Development Managers, Sales Managers, and Regional Managers across European markets, complemented by participation in industry events such as LogiPharma. The company maintains multilingual digital presence (English, French, German, Dutch) and leverages strategic partnerships — most notably the Arra Group alliance — as channel mechanisms. Pricing is not publicly disclosed; prospective clients are directed to contact the company for quotes, consistent with enterprise logistics procurement norms.

Name

Transpharma International

Legal name

Transpharma International Holding B.V.

Website

https://transpharma-international.com

Company type

Private

Founded year

1951

Operating status

Operating

Headcount range

101–250 employees

Short description

Transpharma International is a European GDP-compliant freight forwarder specializing in temperature-controlled road, air, and sea transport for pharmaceutical and healthcare manufacturers. Operating a fleet of 200 owned vehicles plus 3,000+ partner vehicles across Europe, it is now a subsidiary of Yusen Logistics.

Ownership category

akta.pro rank

Product category

Pharmaceutical & Healthcare Logistics

NAICS

Couriers and Express Delivery Services (4921), Scheduled Freight Air Transportation (481112), Refrigerated Warehousing and Storage (493120), Transportation and Warehousing (48-49)

SIC

Transportation Services (4700), Trucking (No Local) (4213), Air Courier Services (4513)

akta.pro primary industry

Pharma & Life Sciences Cold Chain Forwarding (GDP-Compliant) (TLACAMAD)

akta.pro secondary industries

Pharma & Life Sciences Cold Chain Transport (GDP) (TLADAHAI), Temperature-Controlled / Pharma Air Cargo Carriers (TLADAAAG), Controlled Room Temperature (CRT) Transport (15–25°C) (TLADAHAH), Pharmaceutical Cold-Chain Delivery (2–8°C / CRT) (TLAAAJAC), Temperature-Controlled Intermodal (Reefer Container/Trailer) (TLADAFAH)

Keywords

• Pharmaceutical freight forwarding
• Temperature-controlled logistics
• GDP-compliant transport
• Healthcare supply chain
• Medical device logistics

Headquarters

HQ city

Bedford

HQ country

United Kingdom

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Freight Forwarding and Logistics Services: Transpharma International generates revenue by providing GDP-compliant freight forwarding solutions including road, air, and sea transport for pharmaceutical and healthcare products. Services include customs and trade services, temperature-controlled storage, and freight management. The company operates a fleet of 200 owned vehicles complemented by a strategic network of over 3000 partner vehicles across Europe.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Transpharma International provides GDP-compliant freight forwarding and primary transportation for the pharmaceutical and healthcare industries across Europe and globally. The company offers temperature-controlled road, air, and sea transport covering all standard pharmaceutical ranges (-20°C, 2-8°C, 15-25°C), complemented by customs and trade services, cross-docking storage, and the proprietary MyTPI freight management portal for real-time order tracking, document access, and EDI/Oracle integration.

Product overview

Transpharma International is a GDP-compliant logistics and freight forwarding company specializing in temperature-controlled transportation for the healthcare and pharmaceutical industries. The company offers a unified portfolio of transport services spanning road, air, and sea freight, complemented by customs and trade services. Its core technology platform is MyTPI, a freight management system providing clients with order management, real-time tracking, and EDI connectivity. The company operates with 200 owned vehicles and a network of 3,000+ vehicles across Europe, serving manufacturers and distributors with first-mile transport covering all temperature ranges (15-25°C, 2-8°C, -20°C). As of December 2025, Transpharma International became a wholly owned subsidiary of Yusen Logistics (Europe) B.V. as part of the Yusen Logistics Healthcare network, alongside sister companies Movianto (end-to-end logistics), Eurotranspharma (last-mile distribution), and Walden Digital (TMS/WMS solutions).

Differentiator

Problem solved

Functional benefit

Products and services

• Road Transport

Quantifiable outcome

• GDP-compliant shipments across all temperature ranges (15-25°C, 2-8°C, -20°C) for pharmaceutical and healthcare products
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

Feature4 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• Yusen Logistics GroupflagshipStrategic or Co-development Partner · 10 December 2025Yusen Logistics (Europe) B.V. completed the acquisition of Walden Group subsidiaries including Transpharma International (alongside Movianto, Eurotranspharma, and Walden Digital) effective December 10, 2025. The acquisition creates a dedicated Yusen Logistics Healthcare platform connecting end-to-end logistics services including warehousing, transportation, last-mile delivery, control tower, and digital solutions. All entities operate as wholly owned subsidiaries within Yusen Logistics (Europe) B.V. Yusen Logistics is a subsidiary of NYK Group (Japan's largest shipping company).
• Arra GroupcoreStrategic or Co-development Partner · 10 December 2021Transpharma International entered into a strategic partnership with Arra Group, acquiring 40% of Arra Group's shares. Arra Group is a Polish logistics company specializing in temperature-controlled pharmaceutical transport from -25°C to +25°C, operating 300 GDP vehicles with 400 employees. The partnership provides life sciences customers access to a combined network of 500 GDP-compliant vehicles for first-mile supply chain operations, making the companies leading operators in European overland distribution for the life sciences sector (FTL/LTL).

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Biocair: Specialist global courier and forwarder dedicated to the life sciences sector, offering GDP-compliant cold chain transport for clinical trials, biopharma, and advanced therapies. Most directly comparable specialist peer to TPI in pharmaceutical cold chain forwarding.
• Eurotranspharma: Sister company under the Walden Group (now Yusen Logistics Healthcare) specializing in GDP-compliant temperature-controlled last-mile pharmaceutical transport across Europe. Directly comparable as a peer offering overlapping GDP-compliant pharma cold chain services in the same network.

Broad incumbents

• UPS Healthcare (Marken): UPS Healthcare (including Marken for clinical trial logistics) provides temperature-controlled pharma transport, GMP-compliant warehousing, and global medical device distribution. Comparable to TPI as a broad incumbent in GDP-compliant pharma logistics with global reach.
• DB Schenker (now DSV): Global logistics provider with a dedicated LifeCare product line for healthcare and pharma cold chain transport, including GDP-compliant air, sea, and road services. Comparable as a broad incumbent in European pharma cold chain forwarding.
• DSV (Healthcare / Life Sciences): Global transport and logistics provider with a dedicated Healthcare division offering GDP-compliant cold chain solutions across road, air, and sea, with strong European presence following the Schenker integration. Comparable as a broad incumbent competing for the same European pharma cold chain customers as TPI.
• CEVA Logistics (Healthcare): Global logistics provider owned by CMA CGM with a dedicated Healthcare vertical offering GDP-compliant temperature-controlled transport, warehousing, and last-mile distribution for pharma and medical devices. Comparable as a broad incumbent in pharma cold chain.
• Geodis (Healthcare): Global logistics provider with a dedicated Healthcare and Life Sciences vertical offering GDP-compliant temperature-controlled transport and warehousing for pharmaceutical and medical device customers. Comparable to TPI as a broad incumbent in European pharma cold chain.
• DHL Supply Chain (Life Sciences): Global contract logistics leader with a dedicated Life Sciences & Healthcare sector offering GDP-compliant temperature-controlled warehousing, transport, and clinical trials logistics across 50+ countries. Directly comparable as a larger incumbent offering the same GDP-compliant cold chain capabilities as TPI but at global scale.
• Kuehne+Nagel (KN PharmaChain): One of the world's largest freight forwarders with a dedicated PharmaChain product line covering GDP-compliant air, sea, and road transport with temperature-controlled solutions and a global GxP-compliant warehouse network. Comparable to TPI as a global incumbent in pharma cold chain forwarding.

Others

• Cencora (formerly AmerisourceBergen) / World Courier: Cencora owns World Courier, a global specialty courier dedicated to pharmaceutical and biopharmaceutical cold chain transport with GDP compliance, and Alliance Healthcare for European pharmaceutical distribution. Comparable to TPI in pharmaceutical cold chain, particularly clinical trial and specialty pharma logistics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/transpharma-international

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transpharma International